Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q221637> ?p ?o }
Showing triples 1 to 56 of
56
with 100 triples per page.
- Q221637 subject Q5920511.
- Q221637 subject Q6865951.
- Q221637 subject Q8431645.
- Q221637 subject Q8878420.
- Q221637 subject Q8912784.
- Q221637 abstract "Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Mucobrox, Mucol, Lasolvan, Mucoangin, Surbronc, Ambolar, and Lysopain. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract, which play an important role in the body’s natural defence mechanisms. It stimulates synthesis and release of surfactant by type II pneumocytes. Surfactant acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents. Ambroxol is often administered as an active ingredient in cough syrup.Ambroxol is indicated as "secretolytic therapy in bronchopulmonary diseases associated with abnormal mucus secretion and impaired mucus transport. It promotes mucus clearance, facilitates expectoration and eases productive cough, allowing patients to breathe freely and deeply".There are many different formulations developed since the first marketing authorisation in 1978. Ambroxol is available as syrup, tablets, pastilles, dry powder sachets, inhalation solution, drops and ampules as well as effervescent tablets.Ambroxol also provides pain relief in acute sore throat. Pain in sore throat is the hallmark of acute pharyngitis. Sore throat is usually caused by a viral infection. The infection is self limited and the patient recovers normally after a few days. What is most bothering for the patient is the continuous pain in the throat maximized when the patient is swallowing. The main goal of treatment is thus to reduce pain. The main property of Ambroxol for treating sore throat is the local anaesthetic effect, described first in the late 1970s, but explained and confirmed in more recent work.Ambroxol is a potent inhibitor of the neuronal Na+ channels. This property led to the development of a lozenge containing 20 mg of ambroxol. Many state-of-the-art clinical studies have demonstrated the efficacy of Ambroxol in relieving pain in acute sore throat, with a rapid onset of action, with its effect lasting at least three hours. Ambroxol is also anti-inflammatory, reducing redness in a sore throat.Ambroxol has recently been shown to increase activity of the lysosomal enzyme glucocerebrosidase. Because of this it may be a useful therapeutic agent for both Gaucher disease and Parkinson's disease.It was also recently shown that Ambroxol triggers exocytosis of lysosomes by releasing calcium from acidic cellular calcium stores. This occurs by diffusion of Ambroxol into lysosomes and lysosomal pH neutralization. This mechanism is most likely responsible for the mucolytic effects of the drug, but may also explain the reported activity in Gaucher and Parkinson's disease.".
- Q221637 atcPrefix "R05".
- Q221637 atcSuffix "CB06".
- Q221637 casNumber "18683-91-5".
- Q221637 fdaUniiCode "200168S0CL".
- Q221637 iupacName "trans-4-(2-Amino-3,5-dibrombenzylamino)-cyclohexanol".
- Q221637 pubchem "2132".
- Q221637 thumbnail Ambroxol_structural_formulae.png?width=300.
- Q221637 wikiPageWikiLink Q1060331.
- Q221637 wikiPageWikiLink Q13400765.
- Q221637 wikiPageWikiLink Q1513812.
- Q221637 wikiPageWikiLink Q166231.
- Q221637 wikiPageWikiLink Q1788872.
- Q221637 wikiPageWikiLink Q181602.
- Q221637 wikiPageWikiLink Q191154.
- Q221637 wikiPageWikiLink Q1928978.
- Q221637 wikiPageWikiLink Q206077.
- Q221637 wikiPageWikiLink Q2085267.
- Q221637 wikiPageWikiLink Q3460923.
- Q221637 wikiPageWikiLink Q35805.
- Q221637 wikiPageWikiLink Q3649349.
- Q221637 wikiPageWikiLink Q424960.
- Q221637 wikiPageWikiLink Q43054.
- Q221637 wikiPageWikiLink Q477379.
- Q221637 wikiPageWikiLink Q4990531.
- Q221637 wikiPageWikiLink Q581996.
- Q221637 wikiPageWikiLink Q584209.
- Q221637 wikiPageWikiLink Q5920511.
- Q221637 wikiPageWikiLink Q6865951.
- Q221637 wikiPageWikiLink Q7444449.
- Q221637 wikiPageWikiLink Q7891.
- Q221637 wikiPageWikiLink Q8386.
- Q221637 wikiPageWikiLink Q8431645.
- Q221637 wikiPageWikiLink Q851162.
- Q221637 wikiPageWikiLink Q8878420.
- Q221637 wikiPageWikiLink Q8912784.
- Q221637 wikiPageWikiLink Q902364.
- Q221637 atcPrefix "R05".
- Q221637 atcSuffix "CB06".
- Q221637 casNumber "18683".
- Q221637 iupacName "trans-4--cyclohexanol".
- Q221637 pubchem "2132".
- Q221637 unii "200168".
- Q221637 type ChemicalSubstance.
- Q221637 type Drug.
- Q221637 type ChemicalObject.
- Q221637 type Thing.
- Q221637 type Q8386.
- Q221637 comment "Ambroxol is a secretolytic agent used in the treatment of respiratory diseases associated with viscid or excessive mucus. It is the active ingredient of Mucosolvan, Mucobrox, Mucol, Lasolvan, Mucoangin, Surbronc, Ambolar, and Lysopain. The substance is a mucoactive drug with several properties including secretolytic and secretomotoric actions that restore the physiological clearance mechanisms of the respiratory tract, which play an important role in the body’s natural defence mechanisms.".
- Q221637 label "Ambroxol".
- Q221637 depiction Ambroxol_structural_formulae.png.